Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Ayala Pharmaceuticals (NASDAQ: AYLA) announced CEO Roni Mamluk will participate in two virtual investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:00 pm ET for a fireside chat and the Raymond James Human Health Innovation Conference on June 21, 2021, at 10:00 am ET for a corporate presentation. Live webcasts can be accessed on Ayala's website, with replays available for 90 days. Ayala focuses on developing therapies for rare cancers, with candidates AL101 and AL102 targeting specific tumor types.
- None.
- None.
REHOVOT, Israel and WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will participate in two upcoming virtual investor conferences:
- Jefferies Virtual Healthcare Conference: Fireside Chat – Wednesday, June 2, 2021 at 3:00 pm ET.
- Raymond James Human Health Innovation Conference: Corporate Presentation – Monday, June 21, 2021 at 10:00 am ET.
A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for approximately 90 days following the presentations.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.
Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com
Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
FAQ
What are the dates for Ayala Pharmaceuticals' upcoming investor conferences in June 2021?
What is the focus of Ayala Pharmaceuticals?
What product candidates is Ayala Pharmaceuticals developing?
Where can I watch the live webcasts of Ayala Pharmaceuticals' conference presentations?
How long will the webcasts from Ayala Pharmaceuticals' conferences be available for replay?
